Volume 9 Supplement 2
AIDS Vaccine 2012
Meeting abstracts
AIDS Vaccine 2012. Go to conference site.
Boston, MA, USA9-12 September 2012
Page 9 of 9
-
Citation: Retrovirology 2012 9(Suppl 2):P329
-
Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
Citation: Retrovirology 2012 9(Suppl 2):P330 -
From HIV protein sequences to viral fitness landscapes: a new paradigm for in silico vaccine design
Citation: Retrovirology 2012 9(Suppl 2):P331 -
In silico prediction of the neutralization range of human anti-HIV monoclonal antibodies
Citation: Retrovirology 2012 9(Suppl 2):P332 -
Comparison of cellular and humoral immune responses induced by primary, consensus or mosaic HIV-1 Env DNA vaccines
Citation: Retrovirology 2012 9(Suppl 2):P333 -
Engineered microneedle arrays for transcutaneous HIV vaccine delivery
Citation: Retrovirology 2012 9(Suppl 2):P334 -
A new strategy for repeated application of adenovirus based vectors: proof-of-concept in rhesus macaques challenged with SIVmac239
Citation: Retrovirology 2012 9(Suppl 2):P335 -
Oral delivery of transgenic plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to higher doses
Citation: Retrovirology 2012 9(Suppl 2):P336 -
Antigenic mimicry of mammalian oligomannose by a naturally occurring bacterial oligosaccharide and its implications for HIV vaccine design
Citation: Retrovirology 2012 9(Suppl 2):P337 -
Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens
Citation: Retrovirology 2012 9(Suppl 2):P338 -
Different biological activity of CD154-SIVgp41 fusion protein vaccine component in naïve or pre-immune individuals
Citation: Retrovirology 2012 9(Suppl 2):P339 -
Co-immunization with HIV Env DNA and protein elicit long-lasting strong cellular and humoral immune responses
Citation: Retrovirology 2012 9(Suppl 2):P340 -
Viral vector delivery of Env trimer immunogens
Citation: Retrovirology 2012 9(Suppl 2):P341 -
Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
Citation: Retrovirology 2012 9(Suppl 2):P342 -
Rational modification of an HIV-1 gp120 results in enhanced neutralization breadth when used as a DNA prime
Citation: Retrovirology 2012 9(Suppl 2):P343 -
Functional properties of an ensemble of candidate germline-encoded precursors of the anti-MPER antibody 4E10
Citation: Retrovirology 2012 9(Suppl 2):P344 -
Native envelope-based immunogens derived from critical timepoints in the development of breadth elicit rapid neutralizing antibodies in rabbits
Citation: Retrovirology 2012 9(Suppl 2):P345 -
Structural definition of a novel CD4-induced epitope that is targeted by a single-headed immunoglobulin to effect broad and potent HIV neutralization
Citation: Retrovirology 2012 9(Suppl 2):P346 -
Purification of chemically fixed HIV-1 spikes for oriented display on nanoparticles
Citation: Retrovirology 2012 9(Suppl 2):P347 -
DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
Citation: Retrovirology 2012 9(Suppl 2):P348 -
Determination of structural constraint within the HIV proteome through analysis of amino acid microenvironments
Citation: Retrovirology 2012 9(Suppl 2):P349 -
Design and development of a new lentiviral based anti-HIV therapeutic vaccine
Citation: Retrovirology 2012 9(Suppl 2):P350 -
CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
Citation: Retrovirology 2012 9(Suppl 2):P351 -
Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
Citation: Retrovirology 2012 9(Suppl 2):P352 -
Novel computational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
Citation: Retrovirology 2012 9(Suppl 2):P353 -
Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
Citation: Retrovirology 2012 9(Suppl 2):P354 -
Novel AIDS vaccine approach using epithelial stem cells as mucosal antigen-presenting cells
Citation: Retrovirology 2012 9(Suppl 2):P355 -
Simple, scalable and robust purification of two HIV-1 subtype C gp120 monomer subunit antigens for phase II clinical trial in Republic of South Africa
Citation: Retrovirology 2012 9(Suppl 2):P356 -
2G12/PGT-binding yeast glycoprotein Gp38 elicits mannose-specific HIV-1 Env cross-reactive antibodies
Citation: Retrovirology 2012 9(Suppl 2):P357 -
Targeting HIV Gag p24 to DICR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates
Citation: Retrovirology 2012 9(Suppl 2):P358 -
Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
Citation: Retrovirology 2012 9(Suppl 2):P359 -
Natural Killer (NK) cell responses at female genital mucosa to SIV vaginal challenge
Citation: Retrovirology 2012 9(Suppl 2):P360 -
Vector induced skewing of antibody Fc-effector functions
Citation: Retrovirology 2012 9(Suppl 2):P361 -
Retracted: Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
Citation: Retrovirology 2012 9(Suppl 2):P362 -
HIV interactions and the perils of epithelial thinning in the female reproductive tract
Citation: Retrovirology 2012 9(Suppl 2):P363 -
E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost
Citation: Retrovirology 2012 9(Suppl 2):P364 -
CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
Citation: Retrovirology 2012 9(Suppl 2):P365 -
The evolution of HIV-1 subtypes and disease progression among adults on anti-retroviral drugs in Northern Tanzania
Citation: Retrovirology 2012 9(Suppl 2):P366
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 2.7
5-year Journal Impact Factor: 3.1
Source Normalized Impact per Paper (SNIP): 0.707
SCImago Journal Rank (SJR): 0.845Speed 2024
Submission to first editorial decision (median days): 7
Submission to acceptance (median days): 108Usage 2024
Downloads: 1,138,806
Altmetric mentions: 337